MedTrace Logo

Wingspan Stenting for Symptomatic Severe Stenosis of Intracranial Atherosclerosis Registry in China

NCT00685308 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2008-05-28

No results posted yet for this study

Summary

This is a prospective, multi-center, non-randomized trial to study one-year outcomes of the Wingspan system for the treatment of Chinese patients with symptomatic atherosclerotic severe intracranial stenosis.

Conditions

  • Intracranial Atherosclerosis

Interventions

PROCEDURE

Stenting of atherosclerotic intracranial stenosis

Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines. All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%.

Sponsors & Collaborators

  • Ministry of Health, China

    lead OTHER_GOV

Principal Investigators

  • Wei-Jian Jiang, MD · Beijing Tiantan Hospital, The Capital Medical University, Beijing, China

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-10-31
Completion
2010-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00685308 on ClinicalTrials.gov